Novel Aspects in the Pathogenesis of Nonalcoholic Steatohepatitis

被引:5
|
作者
Gentilini, A. [1 ]
Caligiuri, A. [1 ]
Provenzano, A. [1 ]
Marra, F. [1 ]
机构
[1] Univ Florence, Dipartimento Med Sperimentale & Clin, I-50134 Florence, Italy
关键词
NASH; NAFLD; fibrosis; FATTY LIVER-DISEASE; NLRP3 INFLAMMASOME ACTIVATION; LEPTIN RECEPTOR GENE; TOLL-LIKE RECEPTORS; INSULIN-RESISTANCE; HEPATIC STEATOSIS; MESSENGER-RNA; FETUIN-A; CARDIOVASCULAR-DISEASE; PHYSICAL-ACTIVITY;
D O I
10.2174/1566524016666161021163252
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Nonalcoholic steatohepatitis (NASH) is a progressive form of nonalcoholic fatty liver disease, characterized by inflammation, hepatocyte injury and fibrogenesis. Overall mortality, and liver-related mortality, are both increased in NASH patients. Considering that nonalcoholic fatty liver disease is the most prevalent hepatic abnormality in the Western world, understanding the mechanisms leading to NASH and its progression to cirrhosis is critical for a better management of these patients. Moreover, a more detailed knowledge of this condition may be helpful to identify those subjects which are more susceptible to develop progressive liver disease. Emerging data indicate that NASH progression results from parallel events originating from the liver as well as from the adipose tissue, and the gastrointestinal tract. In this review we highlight some of the most recent findings reported on the pathogenesis of NASH and its fibrogenic progression to cirrhosis, in an effort to identify possible targets for treatment or biomarkers of disease progression.
引用
收藏
页码:710 / 720
页数:11
相关论文
共 50 条
  • [31] Natural products in pursuing novel therapies of nonalcoholic fatty liver disease and steatohepatitis
    Li, Haiyan
    Guan, Ting
    Qin, Shi
    Xu, Qihao
    Yin, Lina
    Hu, Qingzhong
    DRUG DISCOVERY TODAY, 2023, 28 (03)
  • [32] Oral choline tolerance test as a novel noninvasive method for predicting nonalcoholic steatohepatitis
    Imajo, Kento
    Yoneda, Masato
    Fujita, Koji
    Kessoku, Takaomi
    Tomeno, Wataru
    Ogawa, Yuji
    Shinohara, Yoshiyasu
    Sekino, Yusuke
    Mawatari, Hironori
    Nozaki, Yuichi
    Kirikoshi, Hiroyuki
    Taguri, Masataka
    Toshima, Gen
    Takahashi, Junichiro
    Saito, Satoru
    Wada, Koichiro
    Nakajima, Atsushi
    JOURNAL OF GASTROENTEROLOGY, 2014, 49 (02) : 295 - 304
  • [33] Rodent Models of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis
    Imajo, Kento
    Yoneda, Masato
    Kessoku, Takaomi
    Ogawa, Yuji
    Maeda, Shin
    Sumida, Yoshio
    Hyogo, Hideyuki
    Eguchi, Yuichiro
    Wada, Koichiro
    Nakajima, Atsushi
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2013, 14 (11) : 21833 - 21857
  • [34] Integrated Multichip Analysis Identifies Potential Key Genes in the Pathogenesis of Nonalcoholic Steatohepatitis
    Ye, Jianzhong
    Lin, Yishuai
    Wang, Qing
    Li, Yating
    Zhao, Yajie
    Chen, Lijiang
    Wu, Qing
    Xu, Chunquan
    Zhou, Cui
    Sun, Yao
    Ye, Wanchun
    Bai, Fumao
    Zhou, Tieli
    FRONTIERS IN ENDOCRINOLOGY, 2020, 11
  • [35] Molecular Pathogenesis of Nonalcoholic Steatohepatitis- (NASH-) Related Hepatocellular Carcinoma
    Kutlu, Ozlem
    Kaleli, Humeyra Nur
    Ozer, Ebru
    CANADIAN JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2018, 2018
  • [36] Pyruvate dehydrogenase kinase 4 mediates lipogenesis and contributes to the pathogenesis of nonalcoholic steatohepatitis
    Zhang, Ming
    Zhao, Yujie
    Li, Zhen
    Wang, Congying
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2018, 495 (01) : 582 - 586
  • [37] Preferred Noninvasive Testing for Nonalcoholic Steatohepatitis
    Le, Long
    Kullar, Ravina
    Saleh, Hussein M.
    Saab, Sammy
    DIGESTIVE DISEASES AND SCIENCES, 2020, 65 (12) : 3719 - 3725
  • [38] Promising therapies for treatment of nonalcoholic steatohepatitis
    Noureddin, Mazen
    Zhang, Alice
    Loomb, Rohit
    EXPERT OPINION ON EMERGING DRUGS, 2016, 21 (03) : 343 - 357
  • [39] Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis 2020
    Tokushige, Katsutoshi
    Ikejima, Kenichi
    Ono, Masafumi
    Eguchi, Yuichiro
    Kamada, Yoshihiro
    Itoh, Yoshito
    Akuta, Norio
    Yoneda, Masato
    Iwasa, Motoh
    Yoneda, Masashi
    Otsuka, Motoyuki
    Tamaki, Nobuharu
    Kogiso, Tomomi
    Miwa, Hiroto
    Chayama, Kazuaki
    Enomoto, Nobuyuki
    Shimosegawa, Tooru
    Takehara, Tetsuo
    Koike, Kazuhiko
    JOURNAL OF GASTROENTEROLOGY, 2021, 56 (11) : 951 - 963
  • [40] Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis 2020
    Tokushige, Katsutoshi
    Ikejima, Kenichi
    Ono, Masafumi
    Eguchi, Yuichiro
    Kamada, Yoshihiro
    Itoh, Yoshito
    Akuta, Norio
    Yoneda, Masato
    Iwasa, Motoh
    Yoneda, Masashi
    Otsuka, Motoyuki
    Tamaki, Nobuharu
    Kogiso, Tomomi
    Miwa, Hiroto
    Chayama, Kazuaki
    Enomoto, Nobuyuki
    Shimosegawa, Tooru
    Takehara, Tetsuo
    Koike, Kazuhiko
    HEPATOLOGY RESEARCH, 2021, 51 (10) : 1013 - 1025